LONDON (dpa-AFX) - GSK plc (GSK.L) Tuesday said its Phase 3 studies dubbed
SWIFT-1 and SWIFT-2 evaluating depemokimab in people with severe asthma met
primary endpoints.

SWIFT-1 and SWIFT-2 trials assessed the efficacy and safety of depemokimab in
participants who were randomised to receive depemokimab or a placebo, in
addition to their standard of care treatment with inhaled corticosteroids plus
at least one additional controller.

Statistically significant and clinically meaningful reductions in exacerbations
or asthma attacks were observed over 52 weeks in patients treated with
depemokimab compared with those who were on placebo. Additionally, the overall
incidence and severity of treatment-emergent adverse events were similar in
patients treated with either depemokimab or placebo across both trials.

'These results add to the established body of evidence that targeted inhibition
of IL-5 plays a key role in reducing type 2 inflammation that drives severe
asthma exacerbations. Depemokimab could offer the possibility of sustained
inhibition of this pathway, with a dosing schedule of just two injections per
year,' said Kaivan Khavandi, SVP, Global Head of Respiratory/Immunology R&D.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX